Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

O. Gottardi, F. Scanzi, S. Zurrida, A. Bono, M. Majno, P. Colombo, M. Ferrari, M. Gambacocta, N. Rossi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.

Original languageEnglish
Pages (from-to)33-36
Number of pages4
JournalBreast
Volume2
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

Ki-67 Antigen
Estrogen Receptors
Disease-Free Survival
Breast Neoplasms
Neoplasms
Monoclonal Antibodies
Cell Proliferation

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer. / Gottardi, O.; Scanzi, F.; Zurrida, S.; Bono, A.; Majno, M.; Colombo, P.; Ferrari, M.; Gambacocta, M.; Rossi, N.

In: Breast, Vol. 2, No. 1, 1993, p. 33-36.

Research output: Contribution to journalArticle

Gottardi, O, Scanzi, F, Zurrida, S, Bono, A, Majno, M, Colombo, P, Ferrari, M, Gambacocta, M & Rossi, N 1993, 'Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer', Breast, vol. 2, no. 1, pp. 33-36. https://doi.org/10.1016/0960-9776(93)90034-D
Gottardi, O. ; Scanzi, F. ; Zurrida, S. ; Bono, A. ; Majno, M. ; Colombo, P. ; Ferrari, M. ; Gambacocta, M. ; Rossi, N. / Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer. In: Breast. 1993 ; Vol. 2, No. 1. pp. 33-36.
@article{8c70d036f8bd48bc948037b5b9e0f4e7,
title = "Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer",
abstract = "The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.",
author = "O. Gottardi and F. Scanzi and S. Zurrida and A. Bono and M. Majno and P. Colombo and M. Ferrari and M. Gambacocta and N. Rossi",
year = "1993",
doi = "10.1016/0960-9776(93)90034-D",
language = "English",
volume = "2",
pages = "33--36",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

AU - Gottardi, O.

AU - Scanzi, F.

AU - Zurrida, S.

AU - Bono, A.

AU - Majno, M.

AU - Colombo, P.

AU - Ferrari, M.

AU - Gambacocta, M.

AU - Rossi, N.

PY - 1993

Y1 - 1993

N2 - The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.

AB - The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.

UR - http://www.scopus.com/inward/record.url?scp=0027256591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027256591&partnerID=8YFLogxK

U2 - 10.1016/0960-9776(93)90034-D

DO - 10.1016/0960-9776(93)90034-D

M3 - Article

AN - SCOPUS:0027256591

VL - 2

SP - 33

EP - 36

JO - Breast

JF - Breast

SN - 0960-9776

IS - 1

ER -